Patent Suit Ends After Lupin Acquires Antara Rights

Law360, New York (October 5, 2009, 3:06 PM EDT) -- Oscient Pharmaceuticals Corp. and Ethypharm SA have dropped a patent infringement suit they brought against Lupin Ltd. over the cholesterol drug Antara, less than two weeks after Lupin announced that it had acquired the U.S. rights to Antara from bankrupt Oscient for nearly $39 million.

Judge Richard Bennett of the U.S. District Court for the District of Maryland on Thursday signed off on two stipulations that said all the claims and counterclaims in the lawsuit were dismissed with prejudice.

On Sept. 25 Mumbai-based Lupin Ltd. said...
To view the full article, register now.